Latest revenue
$1.3K
as of 2023-10-31
Latest net income
$-55.0K
as of 2023-10-31
Net margin
-4194.2%
as of 2023-10-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $437.7K
- Enterprise value
- $437.7K
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.00
- 52-wk low
- $0.00
- Beta
- —
- Shares out
- 2.92B
5-year trend
About NTRR
Business description and risk factors will appear here once NTRR's latest filing is fully ingested.
Profitability
Gross margin
51.9%
53.3%Operating margin
-437.8%
31.0%Net margin
-825.7%
20.0%Return on equity
72.6%
45.9%Return on assets
-746.8%
54.5%Leverage
Debt / equity
-1.10×
0.5%Long-term debt / equity
-0.07×
Debt / assets
1129.4%
5.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2023 2023-10-31 | $1.3K | — | $-55.0K | — | -4194.2% |
Q3 2023 2023-07-31 | $4.3K | — | $-71.8K | — | -1661.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Medicinal Chemicals & Botanical Products · SIC 2833
Your notes
Keep private notes on NTRR — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for NTRR in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns NTRR
No institutional holdings on file for NTRR yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once NTRR's latest filing finishes processing.